Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Galapagos, AZ Enter 3rd Discovery Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Galapagos, AZ Enter 3rd Discovery Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Galapagos NV’s service division, BioFocus DPI, has entered into a new drug discovery collaboration with AstraZeneca, under which BioFocus will perform medicinal chemistry, computational chemistry and support biology and ADMET services for AZ’s infection discovery program based in Boston. Total contract value for Galapagos will be $938,000.

This is the third collaboration between the two companies since August 2006. BioFocus DPI is also providing chemistry and supporting biology and ADME services for an AZ hit-to-lead program.

“We now have a global relationship with AstraZeneca, working with several sites based in Europe and the U.S.,” said Galapagos’ chief executive officer, Onno van de Stolpe. “This type of expansion fits very well with our strategy for growth of the BioFocus DPI service division.”

“Our European colleagues have been pleased with the progress of the drug discovery programs ongoing with BioFocus DPI. The decision for our U.S.-based R&D to enter into this collaboration with BioFocus DPI is based on this productivity and the good working relationship between the two companies thus far,” added Trevor Trust, vice president – Infection Discovery at AstraZeneca U.S.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics